Hormone Replacement Therapy Market Segments And Key Trends 2018-2028
The hormone replacement therapy market is a fragmented landscape with presence of few tier one companies and upcoming players. Top five companies involved in the hormone replacement therapy formulations account for a significant share of the overall hormone replacement therapy market. Top 5 players – Novo Nordisk, Pfizer Inc., Janssen NV (a Johnson & Johnson company), Novartis AG and Bayer AG collectively – collectively account for 35 percent revenue share of the hormone replacement therapy market from on the global front.
Tier 1 hormone replacement therapy companies are focused on carrying out clinical trials for new product development (NPD). Moreover, these companies are adopting vertical, horizontal and backward integration in a bid to achieve rapid expansion and pace in technological development.
In addition, tier 1 hormone replacement therapy companies are forming alliances to co-develop and commercialize hormone replacement therapy drugs. For instance, Pfizer Inc., and Merck KGaA have formed a strategic alliance to develop avelumab (BAVENCIO) to manage hypothyroidism and other thyroid disorders.
Request For Report Sample at https://www.factmr.com/connectus/sample?flag=S&rep_id=2224
Agreement between FDA and NASEM to Impact Hormone Replacement Therapy Market Growth
Food and Drug Administration (FDA) has signed an agreement with NASEM (National Academies of Science, Engineering & Medicine) and is carrying out expanded agreements with University of Maryland and Johns Hopkins University Centers for Regulatory Science and Innovation. Main focus behind this initiative was to conduct research and inform consumers regarding compounded drugs.
NASEM is examining the utility of treating individuals with compounded BHRT (Bioidentical Hormone Replacement Therapy) products. Compounded Bioidentical hormone replacement therapy products such as testosterone and progesterone are used instead of FDA approved hormone replacement therapy drugs as BHRT drugs are considered more safe and natural for patients. This factor is likely to impact the clinical trials of new hormone replacement therapy products in turn challenging the growth of hormone replacement therapy market.
Use of Low Cost Generic Versions of Hormone Replacement Therapy Drugs – An Upcoming Trend
Affordability has always remained a major challenge for any pharmaceutical drug or formulation. Moreover, insufficient healthcare reimbursements have resulted in individuals opting for cheaper drugs with unclear drug effectiveness. This prompted manufactures of hormone replacement therapy drugs to produce generic versions of the formulations in a bid to bridge the gap between purchasing power of people and hormone replacement therapy drug pricing. Companies developing generic hormone replacement therapy drugs are also acquiring FDA approvals, which is direct inference apropos to drug effectiveness. For instance, Teva pharmaceuticals has introduced generic version of Estrace cream and estradiol vaginal cream in 2018. The trend is expected to auger well for the overall growth of the hormone replacement therapy market.
Rising Prevalence of Osteoporosis to Influence Hormone Replacement Therapy Demand
Growing life expectancy is closely associated with degeneration that further translates into osteoporotic fractures. In addition, this condition further results in an increase in gap between spine bones during menopause with diminishing estrogen levels. According to the International Osteoporosis Foundation, osteoporosis causes over 8.9 million fractures annually on the global front and is likely to grow in the coming years. Rising prevalence of osteoporosis among women is expected to trigger the demand for hormone replacement therapy.
Ask an Analyst https://www.factmr.com/connectus/sample?flag=AE&rep_id=2224
Hormone Replacement Therapy Associated with Reduced Dementia – Key Growth Propellant
Hormone replacement therapy can protect memory which is required to carry out short-term cognitive tasks after menopausal stress. Estrogen-only hormone replacement therapy can facilitate lower stress levels without impacting memory. In addition, hormone replacement therapy also reduces possibilities of both vascular dementia and Alzheimer’s disease.
Combination Hormone Replacement Therapy Associated with Cancer – Key Growth Deterrent
Use of hormone replacement therapy can lead to cancerous cell development. The use of combination hormone replacement therapy (combination of progesterone and estrogen) can increase the risk of breast cancer by 75 percent even if used for a short timeframe. According to the U.S Women’s Health Initiative, the use of combination hormone replacement therapy comes with the risk of development of several cancers including ovarian and uterus cancers. This aspect is expected to confine the growth in adoption of hormone replacement therapy in the forthcoming years. Other hormone replacement therapy related disorders such as stroke, cardiac disorders and blood clots are further expected to negatively impact the growth of the hormone replacement therapy market.
To know about other key influencing factors, request a free hormone replacement therapy market report sample
The report on hormone replacement therapy market offers intelligence on key participants in the hormone replacement therapy market. The key companies involved in the formulation of hormone replacement therapy products are thoroughly assessed and profiled in the report. Various facets of competition including SWOT analysis, product portfolio analysis, drug developments and innovations, strategies and key financials are covered. Key companies profiled in the report include Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals, Mylan N.V and Pfizer Inc.
Major companies in the hormone replacement therapy market are concentrating on expanding their current product portfolio. New hormone replacement therapy formulations being the core focus, companies are carrying out trials and gain FDA approvals. For instance, Novartis AG’s research and development department delivered 6 critical FDA breakthrough therapy designations and 16 submissions in 2017. In May 2017, Novartis AG announced U.S. FDA’s approval for its hormone replacement therapy tablets for hormone receptor positive and metastatic breast cancer treatment in postmenopausal women.
In February 2018, Novo Nordisk A/S concluded main phase of REAL 1 – the pivotal phase 3 trial along with somapacitan, a long-acting growth hormone to treat adults with growth hormone deficiency.
Teva Pharmaceuticals Industries Ltd. introduced Vagifem in 2017 for the treatment of atrophic vaginitis. In January 2018, the company launched Estrace cream to treat moderate and severe symptoms of vaginal and vulgar atrophy occurring due to menopause. Likewise, Mylan N.V expanded its US portfolio in the women’s healthcare range with U.S. FDA approval for Estradiol Vaginal Cream to treat vaginal atrophy.
Private equity firms are focused on acquiring emerging participants that are involved in drug delivery systems in the hormone replacement therapy space. For instance, Riverside Company has acquired DoseLogix in a bid to provide innovative dosing dispensers for ensuring accurate dosing medications of hormone replacement therapy and other conditions.
Click to know more on competitive scenario in the hormone replacement therapy market to understand key strategies of market participants
Hormone replacement therapy, also referred to as menopausal hormone therapy, is used to treat various symptoms related to menopause among women. Hormone replacement therapy replaces hormones that are low in level as women near menopause. There are various types of hormone replacement therapy such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy.
About the Report
The report on hormone replacement therapy market provides incisive insights on all aspects influencing growth in demand for hormone replacement therapy worldwide. The report provides a thorough analysis on demand of hormone replacement therapy across key regions in the globe along with sales of various hormone replacement therapy products.
Key drivers, challenges, trends and opportunities shaping the growth of the hormone replacement therapy market are also covered in the hormone replacement therapy market report. The hormone replacement therapy market report provides historical data assessment on use of hormone replacement therapy, current hormone replacement therapy scenario and future demand of hormone replacement therapy. The forecast projections provided cover a timeline of 10 years (2018-2028).
The hormone replacement therapy market is segmented in detail to cover every angle of the hormone replacement therapy space. The hormone replacement therapy market has been segmented on the basis of product type, by dosage form, by indication, by distribution channel and by region.
Various hormone replacement therapy products such as estrogen hormone replacement therapy, thyroid hormone replacement therapy and growth hormone replacement therapy is covered. By dosage form, hormone replacement therapy market is segmented into tablets, patches, injections, implants and creams. By indications, hormone replacement therapy market is categorized into menopause, osteoporosis, thyroid and growth hormone deficiency. By distribution channel, it is segmented by hospital pharmacies, clinics, retail pharmacies and online pharmacies.
The hormone replacement therapy market is assessed across key regions such as North America, Latin America, Europe, Asia Pacific excluding Japan (APEJ), Middle East and Africa (MEA) and Japan.
Additional Questions Answered
Apart from key findings mentioned above, the hormone replacement therapy market report also answers additional questions such as:
Which is the most attractive regional market for hormone replacement therapy?
Which dosage form is largely preferred for using hormone replacement therapy worldwide?
Due to which indication is the hormone replacement therapy market is witnessing a significant upswing in demand?
Which country in the APEJ region accounts for a higher market share in the APEJ hormone replacement therapy?
Which is the most lucrative hormone replacement therapy distribution channel?
The hormone replacement therapy market is drafted using a unique research methodology comprising of a combination of secondary and primary research methodologies. The data gleaned from primary and secondary research is assessed along with information from external sources. All the statistics are compiled using triangulation method to gain highly accurate projections on hormone replacement therapy market.
To Buy This Report at https://www.factmr.com/checkout/2224/S
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Rockville, MD 20852
Follow Us on Linkedin: www.linkedin.com/company/factmr/
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hormone Replacement Therapy Market Segments And Key Trends 2018-2028 here
News-ID: 1373937 • Views: 528
More Releases from Fact.MR
Rising trend towards ready-to-eat foods, and convenient foods fostering fraction …
Consumers, nowadays, are very conscious about their health and this leads them to demand fractionated pulses due to its various health benefits. The fractionated pulses are mainly available in the form of starches and proteins. Due to the increasing demand for vegetable source protein, the demand for fractionated pulses is growing rapidly in the global fractionated pulses market. Owing to the increasing population and demand, the transition from animal-based to
Medical Device Contract Manufacturing Market 2020: Worldwide Industry Analysis o …
The medical device contract manufacturing market is poised to expand at a CAGR of 11.3% during the forecast period (2020-2026). This is attributed to rapidly evolving healthcare industry and increasing adoption of technologically advanced surgical procedures. A number of original equipment manufacturers (OEMs) and contract manufacturers have been focusing on advanced technologies such as robotics, 3D-printing, and minimally invasive surgeries. Mergers & acquisition activities among leading players have greatly accelerated
Upright Ultra-Low Temperature Freezers to Account for 60% of Global Ultra-low Te …
The COVID-19 pandemic, which has been responsible for devastating effects on businesses around the world, has, in fact, proved to be beneficial for the ultra-low temperature freezer market. Key reason being, rising demand for storage units across hospitals, blood banks, etc., due to increasing cases of diseases across the globe. This factor has significantly affected the ultra-low temperature freezer market in a positive manner, which makes it one of the
Spinal Devices Segment, Capturing 1/4th of the Global Orthopedic Devices Market …
The global orthopedic devices market is set to expand modestly, registering a moderate CAGR of 4.0% throughout the forecast period (2020-2026). A rapidly expanding geriatric population pool as well as increasing incidence rates of accidents and sports injuries are major factors contributing to the growth of the global orthopedic devices market. Moreover, technological advancements such as minimally invasive surgeries, artificial intelligence, 3D-bioprinting and tissue engineering, custom-made implants and development of
More Releases for Hormone
Luteinizing Hormone-releasing Hormone Analogs Market Size, Analysis, Research, S …
" Los Angeles, United States – – QY Research offers an overarching research and analysis-based study on the global Luteinizing Hormone-releasing Hormone Analogs market, covering growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented here comes out as a highly reliable source of information and data on the global Luteinizing Hormone-releasing Hormone Analogs market. The researchers and analysts who have prepared the report used
Peptide Hormone Market- Key Development by 2026
Worldwide Peptide Hormone Market report of 2019 provides a detailed market overview as well as industry analysis for / of companies, manufacturers and distributors covering data on gross margin, cost structure, consumption value, sale price and more. The recent research report on the global Peptide Hormone market presents the latest industry data and future trends, allowing you to recognize the products and end users driving Revenue growth and profitability of the
Peptide Hormone Global Industry Report - History, Present and Future 2025
The global market size of Peptide Hormone is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented
Follicle Stimulating Hormone Market
"This report studies the follicle stimulating hormone market. Follicle stimulating hormone (FSH) is a hormone made by the pituitary gland that affects the gonads (female ovaries and males testes). In females, it stimulates growth of the ovarian follicles. In this report, it refers to follicle stimulating hormone drugs for human use. 1 dose is equal to 75 IU." Scope of the Report: This report focuses on the Follicle Stimulating Hormone in United States market,
Industrial Report: Global Hormone Agonists Market
Marketresearchreports.biz has added a new research report on the "Hormone Agonists-Pipeline Insights, 2017" to its collection. DelveInsights, Hormone Agonists-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Hormone Agonists. The DelveInsights Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other
Nutrabolics® launches innovative new hormone amplifier, Aggro
It’s not often the advocates of the supplement industry get excited over a test booster in a market full of proprietary dosages and products that never match their hype; but these bodybuilding community diehards have never had the chance to Get Aggro. After months of clinical research, formulation, and conceptual design, Nutrabolics’ brand new test booster is set to hit store shelves in Canada this July 11th. Unlike typical generic test-boosters,